#47 Clinical Context
Background information relevant to the evolving cannabis medicine landscape.
Clinicians treating young patients must weigh cannabis’s potential benefits for anxiety and sleep against emerging evidence of increased psychosis risk, particularly given the developing adolescent brain’s vulnerability. This finding directly impacts clinical decision-making around cannabis recommendations and requires informed consent discussions that honestly address both therapeutic benefits and serious psychiatric harms. Healthcare providers should implement age-stratified risk assessment protocols and consider alternative first-line treatments for mood and anxiety disorders in younger populations pending further safety data.
A recent study examining cannabis use in young people identifies a significantly elevated risk of psychosis associated with regular consumption during adolescence and early adulthood, a critical period for brain development. While medicinal cannabis demonstrates efficacy for anxiety, sleep disorders, and depression in some populations, clinicians must carefully weigh these therapeutic benefits against the documented psychosis risk, particularly when treating younger patients who may be more neurobiologically vulnerable. The findings underscore the importance of age-stratified prescribing practices and suggest that alternative first-line treatments should be prioritized for adolescents and young adults presenting with mood or anxiety disorders. Healthcare providers should engage in detailed risk-benefit discussions with younger patients and their families before initiating cannabis therapy, with particular caution regarding high-potency products and frequent use patterns. Clinicians managing young patients should maintain heightened vigilance for early psychotic symptoms during and after cannabis exposure, including changes in perception, thought organization, or social functioning. For clinical practice, this evidence reinforces the principle that cannabis, while potentially therapeutic in select indications, should be reserved for adult populations with careful patient selection and requires informed consent discussions that explicitly address psychosis risk in youth.
“We have peer-reviewed evidence showing increased psychosis risk in young people exposed to cannabis, particularly those with genetic vulnerability, and that’s something we cannot ignore in clinical practice. At the same time, we’re seeing separate literature suggesting benefit for anxiety and sleep in some populations, which means the conversation with each young patient needs to be individualized, risk-stratified, and honest about what we still don’t fully understand about long-term developmental effects.”
🧠 While cannabis is increasingly used by young people for self-management of anxiety, sleep, and mood symptoms, emerging evidence suggests that regular use during adolescence and early adulthood may elevate psychosis risk, particularly in genetically vulnerable individuals. This apparent paradox—that cannabis may provide symptom relief in the short term while potentially triggering or exacerbating serious psychiatric illness—complicates clinical decision-making and patient counseling. The causal mechanisms remain incompletely understood, and confounders such as underlying psychiatric vulnerability, frequency of use, cannabinoid composition, and route of administration make it difficult to quantify individual risk. Clinicians should screen for personal or family history of psychotic disorders before recommending or endorsing cannabis use for mood or anxiety symptoms in younger patients, and consider evidence-based alternatives as first-line treatments. When cannabis use is already occurring, maintaining vigilance for early psychotic symptoms and having frank discussions about
This topic comes up in consultations often.
Dr. Caplan offers clinical context on evolving cannabis policy and its real-world implications for patients.
Book a consultation →💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
